dHACM vs. Collagen Matrix for Diabetic Foot Ulcers: What the Evidence Says

Dehydrated human amnion/chorion membrane (dHACM) and collagen wound matrices are both used as adjuncts in the management of chronic diabetic foot ulcers (DFUs) that have failed standard care. They belong to different regulatory categories, they are billed differently, and the published comparative evidence favors dHACM on time-to-closure in several randomized trials.

Category and regulation

• dHACM. Human tissue allograft regulated as an HCT/P under 21 CFR Part 1271 ^[1]. Ambient shelf-stable. Billed under a skin-substitute Q-code.
• Collagen matrices. Typically 510(k)-cleared medical devices (bovine, porcine, or equine collagen). Ambient shelf-stable. Some are billed under a separate Q-code family; others are billed as surgical dressings under HCPCS A-codes.

What the comparative evidence shows

Randomized controlled trials of dHACM in DFUs, most notably the Zelen et al. series, reported significantly higher 4- and 6-week complete closure rates versus standard care and versus a competing living-cell construct ^[2][3]. Trials of collagen-based matrices in DFUs have generally shown modest incremental closure benefit over standard care but have not consistently matched the closure-rate deltas reported for dHACM in comparable populations ^[4].

Key caveats for any buyer comparing these categories:

• Trial populations differ (wound size cutoffs, offloading protocols, HbA1c ranges).
• "Complete closure" endpoints range from 4 to 20 weeks; short-window comparisons favor faster-acting products.
• Real-world outcomes depend heavily on offloading, glycemic control, and infection control — the graft is an adjunct, not a substitute for standard care.

Workflow and cost differences

• Storage: both ambient shelf-stable; dHACM commonly 3–5 yr, collagen 2–3 yr.
• Prep: dHACM rehydrates briefly; collagen is cut to size.
• Applications to closure: dHACM typically 3–6 weekly; collagen typically 4–8 weekly.
• Billing: dHACM under a Q-code; collagen varies (Q-code or A-code).

When to reach for which

• dHACM is a reasonable default for chronic DFUs that have failed 4 weeks of standard care and meet the local MAC LCD criteria ^[6].
• Collagen matrices are frequently used earlier in the pathway, on lower-exudate wounds, or when a Q-code skin substitute is not covered.

Institutional formularies commonly carry both.

FAQ

Is dHACM more effective than collagen for DFUs?

Head-to-head trials directly comparing dHACM to collagen in DFUs are limited. In separate trials against standard care, dHACM has reported larger and faster closure-rate improvements than collagen ^[2][3][4], but the two categories have not been compared under a single protocol at scale.

Are collagen matrices billed the same way as dHACM?

No. dHACM is billed under a skin-substitute Q-code. Collagen matrices are billed under a mix of Q-codes and A-codes depending on the specific product. Always verify against the current CMS HCPCS file.

How many applications should I expect?

For dHACM in DFUs, typical closure is achieved in 3–6 weekly applications. Collagen matrices typically require 4–8 applications. Local MAC LCDs cap the number of applications per episode ^[6].

Do both need offloading?

Yes. Neither category substitutes for total-contact casting or equivalent offloading in a plantar DFU. Payers routinely require documented offloading as a coverage condition.

Which has better shelf life for a small practice?

Both are ambient shelf-stable. dHACM commonly has 3–5 year shelf life; collagen matrices typically 2–3 years.